fbpx Skip nav to main content.
Home > Dr. Megan’s Blog > PSA to patients Stop with the Medrol Dosepaks!

PSA to patients Stop with the Medrol Dosepaks!

PSA to patients Stop with the Medrol Dosepaks!
The Risks of Medrol Dose Packs for Seasonal Respiratory Illnesses

In the realm of healthcare, the prescription of medications is a critical component of patient care. However, not all medications are suitable for every condition, and this is particularly true for Medrol dose packs, which contain the corticosteroid methylprednisolone. Despite their frequent prescription by healthcare providers, Medrol dose packs are not recommended for treating seasonal illnesses such as coughs, colds, flu, or COVID-19. The associated risks significantly outweigh any potential benefits for these conditions.

Watch now!

Understanding Medrol and Its Risks

Medrol is a type of glucocorticoid, a class of steroid hormones that are often used to reduce inflammation. While they can be beneficial in managing chronic conditions like asthma and chronic obstructive pulmonary disease (COPD), especially during acute exacerbations, their use in treating acute respiratory infections is not supported by evidence.

In fact, leading experts and medical literature highlight a lack of efficacy for Medrol in treating various respiratory infections, including influenza, community-acquired pneumonia, bronchitis, cough, COVID-19, sinusitis, otitis media (ear infections), and strep throat.

The risks associated with Medrol are considerable and diverse. Patients have reported severe side effects such as panic attacks, anxiety, insomnia, and intense cravings for food. These adverse effects can profoundly disrupt daily life, hindering individuals’ ability to perform routine activities such as working or spending quality time with family. There are at least 150 potential side effects linked to Medrol within a 30-day treatment period. Moreover, the use of steroids like Medrol elevates the risk of serious complications, including fractures and sepsis, a critical and potentially fatal full-body infection.

Medical Consensus and Guidelines

The current medical consensus, supported by the Infectious Disease Society of America (IDSA), advises against the use of glucocorticoids for treating seasonal influenza and related respiratory conditions unless there is a distinct indication for their use, such as in patients with asthma or COPD. A meta-analysis of observational studies has revealed that the use of glucocorticoids in patients with influenza correlates with an increased risk of mortality, with an odds ratio of 3.9. This statistic indicates that patients taking these medications are nearly four times more likely to die from the flu compared to those who do not.

The Importance of Informed Decision-Making Before Taking Medrol Dosepaks

In conclusion, Medrol dose packs should not be prescribed for seasonal respiratory illnesses. The potential for harm, which includes a broad spectrum of serious side effects and an increased risk of mortality, far outweighs any possible benefits. Patients are encouraged to engage in discussions with their healthcare providers regarding their treatment options and to critically assess the necessity of any prescribed medications, particularly corticosteroids, for acute respiratory conditions. Dr. Megan underscores the importance of informed decision-making and invites further dialogue on this critical topic.

By understanding the risks and limitations of Medrol, patients and healthcare providers can make more informed decisions that prioritize safety and efficacy in the treatment of respiratory illnesses.

Dr. Megan Milne, PharmD, BCACP

Dr. Megan Milne, PharmD, BCACP, is an award-winning clinical pharmacist board certified in the types of conditions people take prednisone for. Dr. Megan had to take prednisone herself for an autoimmune condition so understands what it feels like to suffer prednisone side effects and made it her mission to counteract them as the Prednisone Pharmacist.

Related Posts